Form 4: Tarsus Pharmaceuticals Director Rosemary A. Crane Reports Stock Transaction

Director Rosemary A. Crane reports the acquisition of 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs) on June 24, 2024.

Summary

• On June 24, 2024, Rosemary A. Crane, a director of Tarsus Pharmaceuticals, acquired 3,350 shares of common stock.
• This acquisition resulted from the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Tarsus Pharmaceuticals common stock.
• Following the transaction, Ms. Crane beneficially owns 5,350 shares.
• The RSUs were granted on June 22, 2023, and vested on the one-year anniversary, contingent upon continuous service as a non-employee director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, but insider buying is generally viewed as a positive sign.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates